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Abstract
OBJECTIVES: A second paediatric report has been generated from the European Registry for Patients with Mechanical Circulatory Support
(EUROMACS). The purpose of EUROMACS, which is operated by the European Association for Cardio-Thoracic Surgery, is to gather data
related to durable mechanical circulatory support for scientific purposes and to publish reports with respect to the course of mechanical
circulatory support therapy. Since the first report issued, efforts to increase compliance and participation have been extended.
Additionally, the data provided the opportunity to analyse patients of younger age and lower weight.
METHODS: Participating hospitals contributed pre-, peri- and long-term postoperative data on mechanical circulatory support implants
to the registry. Data for all implants in paediatric patients (<_19 years of age) performed from 1 January 2000 to 1 July 2019 were analysed.
This report includes updates of patient characteristics, implant frequency, outcome (including mortality rates, transplants and recovery
rates) as well as adverse events including neurological dysfunction, device malfunction, major infection and bleeding.
RESULTS: Twenty-nine hospitals contributed 398 registered implants in 353 patients (150 female, 203 male) to the registry. The most fre-
quent aetiology of heart failure was any form of cardiomyopathy (61%), followed by congenital heart disease and myocarditis (16.4% and
16.1%, respectively). Competing outcomes analysis revealed that a total of 80% survived to transplant or recovery or are ongoing; at the 2-
year follow-up examination, 20% died while on support. At 12 months, 46.7% received transplants, 8.7% were weaned from their device
and 18.5% died. The 3-month adverse events rate was 1.69 per patient-year for device malfunction including pump exchange, 0.48 for
major bleeding, 0.64 for major infection and 0.78 for neurological events.
CONCLUSIONS: The overall survival rate was 81.5% at 12 months following ventricular assist device implant. The comparison of survival
rates of the early and later eras shows no significant difference. A focus on specific subgroups showed that survival was less in patients of
younger age (<1 year of age) (P = 0.01) and lower weight (<20 kg) (P = 0.015). Transplant rates at 6 months continue to be low (33.2%) The
fact that the EUROMACS registry is embedded within the European Association for Cardio-Thoracic Surgery Quality Improvement
Programme offers opportunities to focus on improving outcomes.
†The first two authors contributed equally to this study.
VC The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
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ABBREVIATIONS
BiVAD Biventricular assist device
BSA Body surface area
CI Confidence interval
EUROMACS European Registry for Patients with Mechanical
Circulatory Support
HR Hazard ratio
INTERMACS Interagency Registry for Mechanically Assisted
Circulatory Support
LVAD Left ventricular assist device
MCS Mechanical circulatory support
Pedimacs Paediatric Interagency Registry for Mechanical
Circulatory Support
VAD Ventricular assist device
INTRODUCTION
The quantity of data for paediatric patients who suffer from end-
stage heart failure treated with mechanical circulatory support
(MCS) continues to grow. Because the number of patients
implanted with a ventricular assist device (VAD) per centre
remains relatively limited, the European Registry for Patients with
Mechanical Circulatory Support (EUROMACS) provides a plat-
form to collect data from multiple centres across Europe [1].
Within its Quality Improvement Programme, the European
Association for Cardio-Thoracic Surgery provides the structure
for the collection and registration of both paediatric and adult
data of patients who receive MCS. A paediatric subcommittee of
EUROMACS was installed to advise with respect to the evaluation
of paediatric clinical data on adding specific data to increase the
understanding of the course of MCS therapy in children and to
assist in evaluating incoming paediatric study proposals.
EUROMACS collects data from children as well as adults who
received a CE-marked durable assist device (Table 1). This ap-
proach enables the registry to not only select paediatric patients
but also to follow them after they have passed the age of
19 years. Apart from heart transplant and death, weaning was
also defined as a primary end point. To better understand and
analyse the registry-based data on the clinical management and
long-term outcomes in this patient population, follow-up is, as of
2019, continued after ventricle recovery.
Apart from the aim to provide professionals in the field of
MCS with data for scientific research, the EUROMACS registry
strives to generate benchmarking data for participants.
Additionally, patient and device outcomes are structured in such
a way that they are comparable with the Paediatric Interagency
Registry for Mechanical Circulatory Support (Pedimacs) (2) and
Interagency Registry for Mechanically Assisted Circulatory
Support (INTERMACS) outcomes (3).
As a result of the continuous contributions from the participat-
ing hospitals, this second paediatric report provides analysis of
durable MCS until 1 July 2019. Now that the follow-up of
paediatric patients after implantation provides data over a period
of>8 years, longitudinal outcomes and comparisons between eras
(<_2014 and >_2015) have become possible.
Because an increasing number of patients are ongoing on dur-
able VADs, this second EUROMACS paediatric report includes
the data from the first report [1] and includes adverse events and
end points after 31 December 2017.
METHODS
Since 1 January 2018, 6 additional hospitals joined EUROMACS.
As of 1 July 2019, a total of 29 centres in 15 different countries
(Table 2) submitted data to the EUROMACS registry on patients
<_19 years of age implanted with a VAD. The participating centres
agreed to enter data of patients who consented (or their legal
guardians, depending on local legislation in force). Newly
enrolled centres were advised to submit data of patients who
received MCS therapy since 1 January 2011. However, some
centres that have contributed since the inception of EUROMACS
have chosen to submit data from an earlier date, and 38 patients
were registered before 1 January 2011.
Data quality checks and audits
The methods to ensure data reliability were mentioned in the
first Paedi-EUROMACS Report [1]. In summary, these include
statistical consistency and plausibility checks, on-site audits and
feedback reports and update status per patient for each
participant.
Statistical analyses
Baseline and follow-up data were reviewed as to completeness
and chronology. Improbable records were corrected or elimi-
nated after reconfirmation with on-site data managers of
Table 1: Mechanical circulatory support systems relevant to
paediatric populations within EUROMACS
Durable devices
Continuous flow HeartAssist 5
HeartMate II
HeartWare HVAD
HeartMate 3
HeartWare MVAD
Berlin Heart INCOR
Pulsatile Thoratec PVAD
Berlin Heart EXCOR
Total artificial heart -
Short-term devices Levitronix CentriMag
EUROMACS: European Registry for Patients with Mechanical Circulatory
Support: HVAD: HeartWare ventricular assist device; MVAD: miniature ven-
tricular assist device; PVAD: percutaneous ventricular assist device.
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participating centres. Continuous variables are presented as
mean ± standard deviation or median and range depending on
distribution of data. For statistical analyses, the Student’s t-test or
Wilcoxon rank sum test was applied. Categorical variables are
presented as number (n) and percentages of population. Analyses
were performed with the v2 test or the Fisher’s exact test as ap-
propriate. A competing outcomes analysis was performed for a
heart transplant, recovery/weaning, patients still on the device or
death. Kaplan–Meier curves were generated for the complete
group of patients supported by either a left VAD (LVAD) or a
biventricular assist device (BiVAD). Patients for whom the device
type was unknown were not included in any further analysis after
the baseline data were submitted. Furthermore, Kaplan–Meier
analyses were made for all patients, who were split into the fol-
lowing groups: LVAD versus BiVAD, age category, era (patients
implanted <_ 2014 or patients implanted >_ 2015), device strategy,
weight above or below 20 kg, body surface area (BSA) categories
(<1, 1–1.5, >1.5 m2), paracorporeal or intracorporeal LVAD, circu-
latory support before VAD implantation and aetiology of heart
failure. Univariable and multivariable Cox regression analyses
were performed for baseline predictors of death. Finally, all ad-
verse events for the first 3 months and after 3 months were col-
lected and calculated to determine events per patient-year.
Adverse events, which included device malfunction, infection,
neurological dysfunction and major bleeding, were captured
according to INTERMACS Adverse Events definitions. Statistical
analyses were performed with SPSS, version 25 (IBM Inc.,
Armonk, NY, USA) or R-studio [Core Team (2017), R Foundation
for Statistical Computing, Vienna, Austria. URL https://www.R-pro
ject.org/] with the packages ‘survival’ and ‘cmprsk’.
RESULTS
Patient population
Between January 2000 and 1 July 2019, a total of 398 implants in
353 patients were registered (Fig. 1); 150 (42.5%) patients were
female and 203 (57.5%) were male. The mean age was 8.9 years
(±6.4 SD) and ranged from 0 to 19 years, with 55 (15.6%) patients
below the age of 1 year. Baseline characteristics are specified in
Table 3. Primary diagnoses on admission were cardiomyopathy
in 215 (61%), myocarditis in 57 (16.1%), congenital heart disease
in 58 (16.4%) and other in 23 (6.5%) (Table 3). VAD implantation
was predominantly performed in patients with INTERMACS pa-
tient profiles 1, 2 and 3 (21.0%, 49.6% and 19.3%, respectively).
A total of 81.3% of the children were on inotropic support and
25.3% were on mechanical ventilation prior to VAD implantation.
Extracardiac life support was used in 17.2%, whereas an intra-
aortic balloon pump was used in 1.7% of the patients prior to
VAD implantation. Thirty-nine patients received a second device
after the first one; 5 patients received a third and 1 patient, a
fourth implant (Table 4). A full specification of the types of devi-
ces used can be found in Table 5. Of all patients, 51.6% were sup-
ported by the Berlin Heart EXCORV
R
(Berlin Heart, Berlin,
Germany), 4.8% by the HeartMate IIV
R
(Abbott, Chicago, IL, USA),
3.7% by the HeartMate 3 (Abbott, Chicago, IL, USA), 0.6% by
HeartAssist5V
R
(Micromed, Houston, TX, USA) and 31.7% by
HeartWare HVADV
R
(Medtronic, Minneapolis, MN, USA). In 70
patients, 1 (or multiple) concomitant cardiac procedure(s) (12
congenital, 19 valve procedures and 47 other procedures) were
performed. The breakdown and the specifications of the con-
genital heart defects are provided in Table 6. The majority of
Table 2: Participating paediatric units providing data for this
report
Country City, hospital
Austria • Innsbruck, Innsbruck University Clinics
• Vienna, Medical University of Vienna
Belarus • Minsk, Republican Scientific and
Practical Center Cardiology
Belgium • Gent, University Hospital Gent
• Leuven, University Hospital Leuven
Czech Republic • Brno, Center for Cardiovascular and
Transplant Surgery
• Prague, Institute for Clinical and
Experimental Medicine
Germany • Bad Oeynhausen, Herz und Diabeteszentrum
Nordrhein-Westfalen
• Berlin, Deutsches Herzzentrum Berlin
• Freiburg, University Heart Center
Freiburg Bad Krozingen
Hungary • Budapest, Gottsegen Hungarian Institute of Cardiology
Italy • Bergamo, Ospedale Papa Giovanni XIII
• Bologna, San Orsola Hospital
• Rome, Ospedale Pediatrico Bambino Gesu`
• Torino, Regina Margherita Children’s Hospital
Kazakhstan • Astana, National Research Cardiac Surgery Center
Netherlands • Groningen, University Medical Center Groningen
• Rotterdam, Erasmus University Medical Center
• Utrecht, University Medical Center Utrecht
Poland • Warsaw, Children’s Memorial Hospital
• Zabrze, Silesian Center for Heart Diseases
Slovakia • Bratislava, Klinika Kardiochirurgie NUSCH
Spain • La Paz University Hospital
Switzerland • Bern, University Hospital Bern (Inselspital)
• Zu¨rich, Kinderspital Zu¨rich
Turkey • Ankara, Baskent University Hospital
• Istanbul, Florence Nightingale University Hospital
• Izmir, Ege University Hospital
UK • London, Great Ormond Street Hospital
Figure 1: Flow chart. BiVAD: biventricular assist device; LVAD: left ventricular
assist device; RVAD: right ventricular assist device; SVAD: systemic ventricular
assist device.
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Table 3: Baseline characteristics
Overall Era I (n = 156) Era II (n = 197) P-value
Age (years)
Median (range) 10 (0–19) 9 (0.2–19) 10 (0–19) 0.674
Mean ± SD 8.9 ± 6.4 8.8 ± 6.7 9.1 (6.2)
Sex, n (%) 0.279
Male 203 (57.5) 95 (60.9) 108 (54.8)
Female 150 (42.5) 61 (39.1) 89 (45.2)
Age categories (years), n (%) 0.121
1 55 (15.6) 31 (19.9) 24 (12.2)
1–5 82 (23.2) 34 (21.8) 48 (24.4)
6–10 53 (15.0) 18 (11.5) 35 (17.8)
10 163 (46.2) 73 (46.8) 90 (45.7)
Weight categories (kg), n (%) 0.424
<5 11 (3.2) 5 (3.3) 6 (3.0)
5–20 139 (40.5) 63 (40.4) 76 (38.6)
21–40 68 (19.8) 23 (14.7) 45 (22.8)
41–60 62 (18.1) 31 (19.9) 31 (15.7)
>60 63 (18.4) 28 (17.9) 35 (17.8)
Unknown 10 (2.9) 6 (3.8) 4 (2.0)
Body surface area (m2)
Median (range) 1.04 (0.18–2.53) 1.03 (0.21–2.09) 1.04 (0.18–2.53) 0.610
Mean ± SD 1.07 ± 0.58 1.05 ± 0.59 1.08 ± 0.57
Body mass index (kg/m2)
Median (range) 15.8 (8.1–37.7) 15.9 (9.8–31.2) 15.7 (8.1–37.7) 0.489
Mean ± SD 17.0 ± 4.6 17.1 ± 4.4 17.0 ± 4.8
Total bilirubin levels (mg/dl)
Median (range) 1.06 (0.03–25.0) 1.00 (0.03–25.0) 1.20 (0.12–25.0) 0.104
Mean ± SD 1.97 ± 3.22 1.76 ± 3.12 2.14 ± 3.31
Creatinine (mg/dl)
Median (range) 0.67 (0.20–3.75) 0.67 (0.20–3.75) 0.69 (0.20–2.10) 0.932
Mean ± SD 0.76 ± 0.45 0.79 ± 0.55 0.74 ± 0.36
eGFR (ml/min/1.73 m2)
Median (range) 82 (18–211) 83 (19–153) 82 (18–229) 0.218
Mean ± SD 86 ± 35 80 ± 30 88 ± 38
Primary diagnosis, n (%) 0.097
Dilated cardiomyopathy 192 (54.4) 81 (51.9) 111 (56.3)
Congenital heart disease 58 (16.4) 32 (20.5) 26 (13.2)
Myocarditis 57 (16.1) 28 (17.9) 29 (14.7)
Restrictive cardiomyopathy 19 (5.4) 10 (6.4) 9 (4.6)
Hypertrophic cardiomyopathy 4 (1.2) 1 (0.6) 3 (1.5)
Valvular heart disease 5 (1.4) 0 (0) 5 (2.5)
Coronary artery disease 1 (0.3) 0 (0) 1 (0.5)
Cancer 2 (0.6) 0 (0) 2 (1.0)
Unknown 15 (4.2) 4 (2.6) 11 (5.6)
INTERMACS patient profile, n (%) 0.671
INTERMACS 1 74 (21.0) 35 (22.4) 39 (19.8)
INTERMACS 2 175 (49.6) 76 (48.7) 99 (50.3)
INTERMACS 3 68 (19.3) 35 (22.4) 33 (16.8)
INTERMACS 4 15 (4.2) 7 (4.5) 8 (4.1)
INTERMACS 5–7 10 (2.8) 3 (1.9) 7 (3.6)
Unknown 11 (3.1) 0 (0) 11 (5.6)
Number of inotropes, n (%) 0.451
0 38 (10.8) 20 (12.8) 18 (9.1)
1–2 180 (51.0) 76 (48.7) 104 (52.8)
3–4 66 (18.7) 33 (21.1) 33 (16.8)
>_5 3 (0.8) 2 (1.3) 1 (0.5)
Unknown 66 (18.7) 25 (16.0) 41 (20.8)
Mechanical ventilation, n (%) 87 (25.3) 33 (21.2) 54 (28.9) 0.033
Renal replacement therapy, n (%) 13 (3.8) 8 (5.1) 5 (2.7) 0.301
Circulatory support, n (%)
IABP 6 (1.7) 3 (1.9) 3 (1.6) 1.000
ECLS 59 (17.2) 22 (14.1) 37 (19.8) 0.077
Device type, n (%) <0.005
LVAD 275 (77.9) 115 (73.7) 160 (81.2)
LVAD + temporary RVAD 12 (3.4) 2 (1.3) 10 (5.1)
RVAD 1 (0.3) 1 (0.6) 0 (0)
BiVAD 54 (15.3) 37 (23.7) 17 (8.6)
SVAD 8 (2.3) 1 (0.6) 7 (3.6)
Unknown 3 (0.8) 0 (0) 3 (1.5)
Continued
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patients (83.3%) were treated with the intention to transplant (i.e.
bridge to transplant or possible bridge to transplant); this was
true across all age groups (Table 7).
Outcomes
The median support time on a device was 4.2 months (range 0–
83.6 months). The median stay in the intensive care unit was
22 days (range 0–422 days). A total of 265 (80%) children survived
to transplant or recovery or remain on MCS at the 2-year follow-
up (Fig. 2). At 6 months, 33.2% of the patients and at the first
year, 46.7% of the children received a transplant. This percentage
increased to 57.5% at 2 years post VAD implantation. In the over-
all follow-up period, 68 patients died, 38.2% of whom died of
cerebrovascular accidents. Thirteen patients (19.1%) died of mul-
tiorgan failure. The primary cause of death was not specified for
8 patients (Table 8).
Overall survival and subgroup analyses
Kaplan–Meier actuarial survival of all paediatric patients with
MCS was 79.9% at 6 months, 75.5% at 12 months and 67.9% at
2 years, respectively, with censoring at time of explantation for
transplant or for recovery (Supplementary Material, Fig. S1).
When stratified for device type, LVAD or BiVAD, 81.3% survival
was observed in the first year for LVADs and 52.9% for BiVADs
(P < 0.0001) (Fig. 3).
Table 3: Continued
Overall Era I (n = 156) Era II (n = 197) P-value
Current device strategy, n (%) 0.476
Bridge to transplant 190 (53.8) 80 (51.3) 110 (55.8)
Possible bridge to transplant 104 (29.5) 46 (29.5) 58 (29.4)
Rescue therapy 28 (7.9) 15 (9.6) 13 (6.6)
Bridge to recovery 27 (7.6) 15 (9.5) 12 (6.1)
Unknown/other 4 (1.1) 0 (0) 4 (2.0)
BiVAD: biventricular assist device; ECLS: extracorporeal life support; eGFR: estimated glomerular filtration rate; IABP: intra-aortic balloon pump; INTERMACS:
Interagency Registry for Mechanically Assisted Circulatory Support; LVAD: left ventricular assist device; RVAD: right ventricular assist device; SD: standard devi-
ation; SVAD: systemic ventricular assist device.
Table 5: Type of primary implanted ventricular assist device
per age group
Device set-up <1 1–5 6–10 >10 Total
LVAD alone
Pulsatile 41 49 25 23 138
Continuous 6 18 112 136
Unspecified 1 1
LVAD, temporary RVAD
Continuous LVAD, continuous RVAD 7 7
Pulsatile LVAD, continuous RVAD 2 2 1 5
BiVAD
Pulsatile 8 16 6 20 50
Continuous 1 2 3
Unspecified 1 1
SVAD
Pulsatile 2 2
Continuous 2 3 5
Unspecified 1 1
RVAD
Unknown 1 1
Unknown 1 1 1 3
BiVAD: biventricular assist device; LVAD: left ventricular assist device;
RVAD: right ventricular assist device; SVAD: systemic ventricular assist
device.
Table 4: Primary and subsequently implanted devices
Device First Second Third Fourth Total
BiVAD 54 2 0 0 56
LVAD 275 20 2 0 297
LVAD, RVAD 12 1 0 0 13
RVAD 1 6 2 1 10
SVAD 8 1 0 0 9
Unknown 3 9 1 0 13
Total 353 39 5 1 398
BiVAD: biventricular assist device; LVAD: left ventricular assist device;
RVAD: right ventricular assist device; SVAD: systemic ventricular assist
device.
Table 6: Congenital heart diseases (70 diagnoses in 59
patients)
Congenital heart disease n
Complete atrioventricular septal defect 5
Transposition of the great arteries 8
Hypoplastic left heart 7
Single ventricle 4
VSD/ASD 14
Tetralogy of Fallot 1
ALCAPA 3
Ebstein’s anomaly 1
Left heart structural/valvular 3
Other/unknown 24
ALCAPA: anomalous left coronary artery from the pulmonary artery; ASD:
atrial septal defect; VSD: ventricular septal defect.
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When stratified by age, the oldest group (11–19 years) had an
84.5% survival rate at the end of the first year and 78.4% at the
end of the second year; the age group 6–10 years had an 80.3%
1-year survival rate; the age group 1–5 years had a 69.4% survival
rate at the end of the first year. Patients <1 year old had the
poorest survival rate of 49.3% at 1 year (P = 0.01) (Fig. 4).
Supplementary Material, Figure S2 shows the survival analysis
of all patients by era. Era 1 includes all patients who received
implants before 2015; era 2 includes all patients who received
implants as of 1 January 2015. The 2-year survival rate was 71.2%
in era 1 and 65.4% in era 2 (P = 0.92). The 1-year survival rate
stratified by device strategy reveals survival rates of 82% for
bridge to recovery, 78.9% for bridge to transplant, 74.7% for pos-
sible bridge to transplant and the worst survival rate (51%) for
rescue therapy (P = 0.0019) (Fig. 5). Figure 6 depicts the survival
analysis of patients who weighed less than or more than 20 kg
and reveals a significantly worse survival rate for patients weigh-
ing <20 kg (P = 0.015). Similarly, patients with a lower BSA (<1 m2
or between 1 and 1.5 m2) have a significantly worse survival rate
than patients with a BSA of 1.5 m2 or higher (P = 0.0099) (Fig. 7).
Survival of patients supported by a paracorporeal device com-
pared to patients supported by an intracorporeal device reveals a
significantly worse survival for paracorporeal support (71% vs
88%; P = 0.017) (Supplementary Material, Fig. S3). If groups with
intracorporeal and paracorporeal devices are separated by
weight categories, patients >10 kg do not have a significantly dif-
ferent outcome but do differ significantly between weight cate-
gories (P = 0.0022) (Fig. 8). A comparison of survival rates of
patients with or without pre-VAD implant circulatory support
(e.g. extracorporeal life support or an intra-aortic balloon pump)
reveals that patients with support have a significantly worse out-
come (P = 0.0081) (Fig. 9). Survival according to the aetiology of
Table 7: Device strategy at the time of first implant, stratified
by age categories
Device strategy <1 1–5 6–10 >10 Total
Bridge to recovery 8 7 2 10 27
Bridge to transplant
(patient currently listed for transplant)
28 47 25 90 190
Possible bridge to transplant 16 20 21 47 104
Rescue therapy 2 7 4 15 28
Unknown/other 1 1 1 1 4
Total 55 82 53 163 353
Figure 2: Competing outcomes analysis for death, heart transplant, recovery/weaning or patients on device support. HTx: heart transplant.
Table 8: Primary causes of death
Primary cause of death n (%)
Neurological dysfunction 26 (38.2)
Multiorgan failure 13 (19.1)
Major bleeding 4 (5.9)
Major infection 4 (5.9)
Cardiopulmonary failure 3 (4.4)
Device malfunction 2 (2.9)
Right heart failure 1 (1.5)
Other 7 (10.3)
Unknown/missing 8 (11.8)
Total 68
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Figure 4: Survival analysis by age category.
Figure 3: Survival analysis of LVAD versus BiVAD. BiVAD: biventricular assist device; LVAD: left ventricular assist device.
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Figure 6: Survival by weight: below 20 kg or 20 kg and above.
Figure 5: Survival analysis by device strategy. BTR: bridge to recovery; BTT: bridge to transplant.
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Figure 8: Survival for IC versus PC devices by weight category. IC: intracorporeal; PC: paracorporeal.
Figure 7: Survival stratified by BSA. BSA: body surface area.
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Figure 9: Survival of patients stratified by pre-VAD implant circulatory support. VAD: ventricular assist device.
Figure 10: Survival of patients stratified by aetiology of heart failure. CHD: congenital heart disease; CMP: cardiomyopathy.
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heart failure did not reveal a statistically significant difference
(P = 0.083) (Fig. 10).
An univariable Cox regression model revealed that older
patients and patients supported by an LVAD (compared to
BiVAD) [hazard ratio (HR) 0.33, 95% confidence interval (CI)
0.19–0.58; P = 0.001] had a significantly lower risk of death,
whereas patients with device strategy rescue therapy had a sig-
nificantly higher risk of death (HR 2.82, 95% CI 1.38–5.77;
P = 0.004) (Table 9). These findings were confirmed in a multivari-
able model. Compared to patients <1 year old, the HR for death
was statistically significant for patients aged 1–5 years: 0.40 (95%
CI 0.19–0.84; P = 0.02) and for patients >10 years: 0.32 (95% CI
0.16–0.64; P = 0.001) and trended towards significance for
patients aged 6–10 years (HR 0.48, 95% CI 0.21–1.09; P = 0.08)
(Table 9). Rescue remained a predictor for a significantly worse
survival rate (HR 3.24, 95% CI 1.56–6.74; P = 0.002), whereas the
use of an LVAD was associated with a lower probability of death
(HR 0.37, 95% CI 0.20–0.68; P = 0.001).
Adverse events
Overall, 425 adverse events were reported during VAD support.
Within the first 3 months after VAD implantation, 225 events
occurred whereas 200 occurred after 3 months (Table 10).
The most frequently reported major adverse event was device
malfunction, which included, as per definition, pump exchanges
from paracorporeal devices due to pump thrombosis. Device
malfunction occurred 106 times in the first 3 months, which
resulted in 1.69 events per patient-year. After 3 months, 0.60 de-
vice malfunctions per patient-year were reported.
The event rates for neurological dysfunction and infection
were 0.78 (n = 49) and 0.64 (n = 40) per patient-year, respectively,
for the first 3 months. After 3 months, 0.13 events of neurological
dysfunction (n = 24) and 0.35 infections per patient-year (n = 62)
were reported. Finally, 30 events of major bleeding were
reported in the first 3 months (0.48 events per patient-year) and
7 events after 3 months (0.04 events per patient-year).
DISCUSSION
This second Paedi-EUROMACS report is an update of the previ-
ous report, but it simultaneously explores some outcomes in
more detail. In comparison to the first report, the number of reg-
istered paediatric implants increased from 210 to 353, whereas
the baseline demographic characteristics remained relatively un-
changed. This growth is caused by the continuous inclusion of
patients in centres that were already participating but is also the
result of new centres that started to contribute data to
EUROMACS. Twenty-nine centres contributed data to this second
paediatric report, an increase of 20%. Device strategies as well as
device characteristics have not changed considerably [1].
Comparing the data with those of the North American
Pedimacs Registry reveals relatively similar baseline characteris-
tics in respect to age, devices implanted, device strategy and aeti-
ology of heart failure. However, some differences should be
noted. First, in Pedimacs, a larger percentage of patients had
INTERMACS patient profile 1 (33%) vs 21% in our study [2].
Furthermore, the percentage of patients requiring mechanical
ventilation prior to VAD implantation was reported to be almost
Table 10: Major adverse events
Major adverse events Within 3 months After 3 months Total
Event counts Events per patient-year Event counts Events per patient-year
Device malfunction 106 1.69 107 0.60 213
Major bleeding 30 0.48 7 0.04 37
Major infection 40 0.64 62 0.35 102
Neurological dysfunction 49 0.78 24 0.13 73
Total 225 200 425
Table 9: Univariable and multivariable analyses of baseline predictors for death
Characteristics Univariable Multivariable
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age (years)
<1 Reference Reference
1–5 0.51 (0.25–1.06) 0.07 0.40 (0.19–0.84) 0.02
6–10 0.39 (0.17–0.89) 0.03 0.48 (0.21–1.09) 0.08
>10 0.28 (0.14–0.55) < 0.001 0.32 (0.16–0.64) 0.001
Device strategy
Bridge to transplant Reference Reference
Bridge to recovery 1.07 (0.38–2.99) 0.89 1.08 (0.38–3.06) 0.88
Rescue therapy 2.82 (1.38–5.77) 0.004 3.24 (1.56–6.74) 0.002
Device type
BiVAD Reference Reference
LVAD 0.33 (0.19–0.58) <0.001 0.37 (0.20–0.68) 0.001
BiVAD: biventricular assist device; CI: confidence interval; LVAD: left ventricular assist device.
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twice as high in Pedimacs (45% compared to 25.3% in Paedi-
EUROMACS). Extracorporeal life support prior to a VAD implant
was 17.2% in this study, whereas it was 12.6% for Pedimacs (but
only for those implanted with a continuous flow device) [3].
If we continue comparing outcomes in this report to those in
the first report, we see that approximately the same percentage
of patients has recovered or had a transplant after 2 years and
the same holds true for the percentage of patients who died. In
comparison to Pedimacs though, there remains a striking differ-
ence in early transplant rates, with 50% of the patients having
transplants after 6 months in North America, whereas fewer than
35% had transplants in our current study. Of interest, though, is
the fact that after 12 months of VAD support, differences in the
rates of transplants have become smaller: 51.4% in Pedimacs and
46.7% in Paedi-EUROMACS, an improvement compared to the
analysis in the first report (38%) [1].
Adverse events rates in this study are considerably higher than
those reported in the first report. One explanation for this in-
crease could be that the additional patients in this second report
were sicker and encountered more adverse events. However, as
previously mentioned, the baseline characteristics of the patients
discussed in this report do not differ considerably from those
studied in the previous report, making this an unlikely explan-
ation. Furthermore, the current adverse event rates are in a range
comparable to the rates reported in North America. For instance,
device malfunction was reported to be 2.4 events per patient
year in the first 3 months, whereas this report has a 1.69 event
rate per patient-year. The cause of device malfunction is infre-
quently registered within the EUROMACS follow-up.
In this second paediatric report, some specific subgroups were
studied more closely. The analysis of patients in era I compared
to that of patients in era II did not reveal any significant differen-
ces except for the fact that fewer BiVAD set-ups were implanted
in era II than in era I (8.6% vs 23.7%, respectively). Survival rates
were similar for era I and era II, which indicates that, although
the experience with the devices has increased over the years,
outcomes have not. A recent study based on the Berlin Heart
EXCOR prospective registry did find a significantly improved sur-
vival rate for patients weighing <10 kg implanted from 2013 to
2017 compared to those implanted from 2000 to 2012 [4].
However, that study considered eras different from those com-
pared in our current study. In addition, improvements in the de-
sign of the Berlin Heart EXCOR were implemented from 2000 to
2012, including the addition of a 15-ml stroke volume chamber
[5, 6].
When considering patients in different age categories, it is ap-
parent that younger patients have worse outcomes than older
patients, which was confirmed in the multivariable analysis. This
difference is especially striking for patients below the age of
1 year compared to the other groups, with a 6-month survival of
54.3% compared to survival percentages ranging from 79.4% to
85.8% for the age categories >1 year. These results are similar to
those of the North American experience (50% survival at
6 months <1 year) [2] and highlight that there is still much room
for improvement in this select population.
Similarly, patients weighing <20 kg did significantly worse than
those weighing>20 kg. These results are in line with those of a
previous report that showed that patients weighing <5 or 10 kg
had worse survival rates [7, 8]. Furthermore, it is interesting to
note that survival for paediatric patients >10 kg did not differ sig-
nificantly between those with paracorporeal and intracorporeal
devices. This result would indicate that the main reason for a
worse outcome is not the type of VAD, which is similar to the
conclusions of previous reports [9].
Furthermore, patients with a small BSA (<1 m2) had lower sur-
vival rates than patients with a BSA higher than 1 m2. It was pre-
viously reported that a mismatch of the size of the stroke volume
chamber of the Berlin Heart EXCOR with BSA is associated with
an increase in thromboembolic events but not in the number of
deaths [6]. Unfortunately, these data are rarely available in
EUROMACS, which makes a granular analysis of such an associ-
ation not possible.
Finally, outcomes by aetiology showed a trend towards poorer
outcomes for patients with myocarditis as the aetiology of heart
failure, although patients with congenital heart disease had only
a marginally better outcome at 12 months (69% vs 65% survival).
This interesting observation is different from previously reported
data, where congenital heart disease was associated with the
poorest survival rate [3, 8].
Limitations
The registry continues recruiting to increase the numbers of con-
tributing centres, the goal being to include as many European
centres as possible. In contrast to the situation in the USA, par-
ticipation in EUROMACS is not mandatory in Europe. Therefore,
surveillance and improvement of data quality are ongoing
efforts.
CONCLUSION
The current report shows that there has been an overall improve-
ment of transplant rates at 1 year and that VAD therapy is a vi-
able option for paediatric patients with severe heart failure, with
80% of the patients receiving transplants, weaned or ongoing at
2 years. Furthermore, the European experience is in many ways
comparable to the North American experience; however, trans-
plant rates at 6 months remain more advantageous in the
Pedimacs cohort. Adverse event rates, however, remain high:
Almost 40% of the deceased patients died of neurological ad-
verse events. Moreover, results in young and small children are
considerably worse than results in the other groups. Finally, we
compared era 1 with era 2 to determine if experience with the
devices has resulted in better outcomes. Unfortunately, our ana-
lysis does not show an improvement of outcomes over time.
To answer some of the questions as to why some subgroups
perform significantly worse than other groups, a paediatric sub-
committee of EUROMACS has been set up. Embedded in the
European Association for Cardio-Thoracic Surgery Quality
Improvement Programme, this committee will identify if and
what data fields have to be changed within the registry and will
set out study proposals for the contributing hospitals to partici-
pate in. This effort will hopefully result in the availability of new
data for making clinical decisions for the special population of
paediatric patients.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
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